| Bioactivity | NLRP3-IN-21 (compound L38) is a NLRP3 inflammasome inhibitor with inflammatory properties. NLRP3-IN-21 inhibits NLRP3 inflammasome activation and pyroptosis by suppressing gasdermin D cleavage, ASC oligomerization, and NLRP3 inflammasome assembly[1]. |
| Name | NLRP3-IN-21 |
| CAS | 2956791-61-8 |
| Formula | C20H13Cl2F3N6O2S |
| Molar Mass | 529.32 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Na Li, et al. Discovery of Triazinone Derivatives as Novel, Specific, and Direct NLRP3 Inflammasome Inhibitors for the Treatment of DSS-Induced Ulcerative Colitis. J Med Chem. 2023 Oct 12;66(19):13428-13451. |
NLRP3-IN-21
CAS: 2956791-61-8 F: C20H13Cl2F3N6O2S W: 529.32
NLRP3-IN-21 (compound L38) is a NLRP3 inflammasome inhibitor with inflammatory properties. NLRP3-IN-21 inhibits NLRP3 in
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.